Novartis Animal Health has reduced the price by up to 34 percent on its Atopica (Cyclosporine capsules, USP) Modified, a nonsteroidal oral therapy developed to control canine atopic dermatitis.
"Atopic dermatitis is an expensive disease to treat," said John Rehak, DVM, Atopica senior product manager. "By passing the new cost savings along to their clients, veterinarians will be able to help more patients suffering from the relentless misery caused by atopy. Comfortable dogs mean satisfied, happy and loyal clients, which makes for a healthier clinic, too."
The new pricing, which covers all product sizes, will take effect Feb. 1.